| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 04/01/2004 | WO2004026289A1 Nutritional or therapeutic compositions |
| 04/01/2004 | WO2004026259A2 Transdermal compositions |
| 04/01/2004 | WO2004026243A2 Therapeutic uses of linear ketophosphonates |
| 04/01/2004 | WO2004026242A2 Substituted ketophosphonate inhibitors of tumor cell proliferation |
| 04/01/2004 | WO2004026241A2 Multistage formulation containing a biguanide and thiazolidindione derivatives |
| 04/01/2004 | WO2004026238A2 Immunotherapeutic compositions and methods for the treatment of moderately to well-differentiated cancers |
| 04/01/2004 | WO2004026234A2 Method of treating leukemia with a combination of suberoylanilide hydromaxic acid and imatinib mesylate |
| 04/01/2004 | WO2004009762A9 Flea and tick octopamine receptor nucleic acid molecules, proteins and thereof |
| 04/01/2004 | WO2004007723A3 Genes |
| 04/01/2004 | WO2004006832A3 Methods and compounds for reducing biofilm formation |
| 04/01/2004 | WO2004005881A3 Methods for identification of compounds modulating insulin resistance |
| 04/01/2004 | WO2004002399A3 Use of gaba-c receptor antagonists for the treatment of myopia |
| 04/01/2004 | WO2004000354A3 Method of treating the syndrome of lipodystrophy |
| 04/01/2004 | WO2003103644A3 Guanidino phenylalanin compounds used as urokinase inhibitors |
| 04/01/2004 | WO2003103613A3 Induction of insulin expression |
| 04/01/2004 | WO2003103602A3 Nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use |
| 04/01/2004 | WO2003099281A3 Administration of a partial fatty acid inhibitor such as ranolazine for the treatment of diabetes |
| 04/01/2004 | WO2003097799A3 HTLV-I TAX INDUCED KILLING OF p53 NULL CANCER CELLS |
| 04/01/2004 | WO2003094968A3 Combination of a proton pump inhibitor and a respiratory agent for the treatment of respiratory diseases |
| 04/01/2004 | WO2003094967A3 New combination of reversible proton pump inhibitors and airway therapeutics for treating airway disorders |
| 04/01/2004 | WO2003094909A3 Methods and compositions for the treatment and prevention of intermittent claudication or alzheimer's disease |
| 04/01/2004 | WO2003090737A3 Methods and compositions for treatment of cancer pain |
| 04/01/2004 | WO2003089934A3 Method for diagnosing inflammatory diseases and infections by the determination of lasp-1/lap-1 |
| 04/01/2004 | WO2003087840A3 Protein involved in cancer |
| 04/01/2004 | WO2003086452A3 Methods of enhancing lysosomal storage disease therapy |
| 04/01/2004 | WO2003084540A3 Compositions comprising mmp7 modulators for the treatment of chronic pain |
| 04/01/2004 | WO2003084385A3 Redifferentiated cells for repairing cartilage defects |
| 04/01/2004 | WO2003084343A3 Method and dietary composition for improving fat digestibility |
| 04/01/2004 | WO2003082926A3 Antimicrobial polymer conjugates |
| 04/01/2004 | WO2003082314A3 Diagnostics and therapeutics for diseases associated with n-formyl peptide receptor like 1 (fprl1) |
| 04/01/2004 | WO2003079998A3 Treatment of diseases involving defective gap junctional communication |
| 04/01/2004 | WO2003077893A3 Compositions for treating digestive functional pathologies |
| 04/01/2004 | WO2003072029A3 Methods of extending corneal graft survival |
| 04/01/2004 | WO2003068148A3 Treatment of sleep disorders using sleep target modulators |
| 04/01/2004 | WO2003066021A3 Drug nanoparticles with lysozyme surface stabiliser |
| 04/01/2004 | WO2003063844A3 Treatment of rheumatoid arthritis using imatinie |
| 04/01/2004 | WO2003063792A3 Compositions and methods related to tim-3, a th1-specific cell surface molecule |
| 04/01/2004 | WO2003061654A9 Pramipexole for the treatment of hiv dementia |
| 04/01/2004 | WO2003057205A3 Combination of mtp inhibitors or apob secretion inhibitors with fibrates for use as drugs |
| 04/01/2004 | WO2003056029A3 Highly sensitive and continuous protein-tyrosine-phosphatase (ptpase) test using 6,8 difluoro-4-methyl-umbelliferylphosphate |
| 04/01/2004 | WO2003049675A3 Treating muscle wasting with selective androgen receptor modulators |
| 04/01/2004 | WO2003031940A3 Structural and cytoskeleton-associated proteins |
| 04/01/2004 | WO2003026635A3 Improved method of treating the syndrome of type 2 diabetes in humans |
| 04/01/2004 | WO2003025019A8 Anti-pdgf antibodies and methods for producing engineered antibodies |
| 04/01/2004 | WO2003016563A3 Novel molecular target for neurotoxicity |
| 04/01/2004 | WO2002102314A3 Purine inhibitors of phosphodiesterase (pde) 7 |
| 04/01/2004 | WO2002089798A3 Method and compositions for treating migraines |
| 04/01/2004 | WO2002083847A3 Cdna encoding the human alpha2 delta4 calcium channel subunit |
| 04/01/2004 | WO2002060485A9 Use of immunoregulatory antibodies in the treatment of neoplastic disorders |
| 04/01/2004 | US20040064039 Myocardial perfusion imaging method |
| 04/01/2004 | US20040063943 Phosphodiesterase inhibitor; cardiovascular disorders; sexual disorders |
| 04/01/2004 | US20040063934 Integrin ligands |
| 04/01/2004 | US20040063794 Vehicle for topical delivery of anti-inflammatory compounds |
| 04/01/2004 | US20040063755 Aromatic compounds containing hydroxyalkylaminoalkylphenylaminophenyl group; useful for treating pre-term labor, neurological disorders and cardiac disorders |
| 04/01/2004 | US20040063751 Such as N-(2-cyclohexyloxynitrophenyl)methane sulfonamide |
| 04/01/2004 | US20040063747 Local anesthetic methods and kits |
| 04/01/2004 | US20040063742 Such as 5-(4-Chlorophenyl)-8-methyl-6,7,8,9-tetrahydro-1-H-pyrrolo(3.2-h)isoquinoline-2,3-dione-3-oxime-(phenyl))urea; kits; drug screening |
| 04/01/2004 | US20040063734 4,4-Disubstituted-3,4-dihydro-2 (1H)-quinazoliniones useful as HIV reverse transcriptase inhibitors |
| 04/01/2004 | US20040063731 Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidines and endothelin receptor antagonists or thienopyrimidines and endothelin receptor antagonists |
| 04/01/2004 | US20040063730 Such as 5-(7-(3-chloro-4-methoxybenzylamino-1-methyl-3-propyl-1 H-pyrazolo(4,3-d)pyrimidin-5-yl)pentanoic acid; phosphodiesterase inhibitors; for treatment of cardiovascular disorders, asthma, and allergies; kits |
| 04/01/2004 | US20040063721 Using endogenously produced serotonin reuptake inhibitor ligand |
| 04/01/2004 | US20040063720 Tyrosine kinase inhibitors |
| 04/01/2004 | US20040063719 Combination therapy using antihypertensive agents and endothelin antagonists |
| 04/01/2004 | US20040063718 Targeted therapeutics and uses thereof |
| 04/01/2004 | US20040063717 Employing fatty acid oxidation inhibitor; lowering HbA1c, glucose, total cholesterol and/or triglyceride plasma levels; increasing high density lipoprotein concentration; minimizing side effects; ranolazine |
| 04/01/2004 | US20040063712 Disruption of signal transduction by inhibition of kinases in target cells |
| 04/01/2004 | US20040063709 Acute and chronic inflammatory disorders; cancer |
| 04/01/2004 | US20040063708 Pyrrolotriazine kinase inhibitors |
| 04/01/2004 | US20040063707 Azaindole kinase inhibitors |
| 04/01/2004 | US20040063700 Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method |
| 04/01/2004 | US20040063697 Compositions of cyclooxygenase-2 selective inhibitors and thrombolytic agents for the treatment or prevention of a vaso-occlusive event |
| 04/01/2004 | US20040063691 Preparation and use of imidazole derivatives for treatment of obesity |
| 04/01/2004 | US20040063689 Compositions containing alpha-2-adrenergic agonist components |
| 04/01/2004 | US20040063687 Cardiac arrhythmias; potassium channel function inhibitors; such as 7-(3,4-Dichlorophenyl)-6-(5-fluoro-1-methyl-1H-benzimidazol-2-yl)-4,7 -dihydro-5-(methoxymethyl)pyrazolo-(1,5-a)pyrimidine |
| 04/01/2004 | US20040063686 Diabetes, major depression, manic depression, anxiety, schizophrenia, sleep disorders |
| 04/01/2004 | US20040063685 Cycloalkene antisepsis drug with antibacterial, antifungal, nonsteroidal antiinflammatory, steroid and/or anticoagulant agents |
| 04/01/2004 | US20040063684 Treatment of oesophageal motility disorders and gastro-oesophageal reflux disease |
| 04/01/2004 | US20040063676 Asthma symptomatic relief; formoterol and budesonide |
| 04/01/2004 | US20040063672 Method for the treatment of polycystic kidney disease |
| 04/01/2004 | US20040063661 Treatment of statin side effects |
| 04/01/2004 | US20040063649 Azithromycin combination for emesis control in mammals |
| 04/01/2004 | US20040063648 Compositions comprising plant-derived polyphenolic compounds and inhibitors of reactive oxygen species and methods of using thereof |
| 04/01/2004 | US20040063641 Healing fractures in distractive osteogenesis; accelerating regeneration and consolidation; torsional and mechanical stiffness; mass |
| 04/01/2004 | US20040063610 For therapy of mammal having a transected peripheral nerve or injured spinal cord |
| 04/01/2004 | US20040063178 Comprises enzymatic polypeptide for identifying modulators of leukocyte adhesion and treatments of inflammatory diseases l |
| 04/01/2004 | US20040063142 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins and uses thereof |
| 04/01/2004 | US20040063131 Comprises neuroendocrine-specific proteins-like polypeptides (NSPLP) for diagnosis, prevention and treatment of neurodegenerative and cell proliferative diseases |
| 04/01/2004 | US20040062848 Lapactic agent |
| 04/01/2004 | US20040062847 Oil/fat composition |
| 04/01/2004 | US20040062817 Wound healing compound |
| 04/01/2004 | US20040062810 Removal blockage in blood vessels; mixture of angiogenesis inhibitor and polymer |
| 04/01/2004 | US20040062803 Sustained-release formulation of a cyclooxygenase-2 inhibitor |
| 04/01/2004 | US20040062800 Compressed matrix tablet; mixture of drug and swellable polymer; side effect reduction |
| 04/01/2004 | US20040062731 Topical anti-cancer compositions and methods of use thereof |
| 04/01/2004 | US20040062724 Thin, flexible, multilayer film; applying, adhesion to teeth; supplying active materials |
| 04/01/2004 | US20040062719 Carrier for drug delivery; crystal structure core with surface coating; induce crystallization of amorphous particles; hermetic sealed packages |
| 04/01/2004 | US20040061039 Furnace mount and method of installation |
| 04/01/2004 | US20040060865 Buffered compositions for dialysis |
| 04/01/2004 | US20040060568 Hedgehog antagonists, methods and uses related thereto |
| 04/01/2004 | DE202004000552U1 Mittel zum Bleichen von Zähnen Means for bleaching teeth |